A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Childhood 25-hydroxy-vitamin D levels predict early cardiovascular outcomes in adulthood: the Cardiovascular Risk in Young Finns Study




TekijätNiemelä, Jussi; Laitinen, Tomi T.; Nuotio, Joel; Pahkala, Katja; Rovio, Suvi; Viikari, Jorma; Kähönen, Mika; Lehtimäki, Terho; Loo, Britt-Marie; Laitinen, Tomi P.; Jokinen, Eero; Tossavainen, Päivi; Magnussen, Costan G.; Juonala, Markus; Raitakari, Olli

KustantajaOxford University Press

Julkaisuvuosi2025

Lehti: European Journal of Preventive Cardiology

ISSN2047-4873

eISSN2047-4881

DOIhttps://doi.org/10.1093/eurjpc/zwaf271

Julkaisun avoimuus kirjaamishetkelläAvoimesti saatavilla

Julkaisukanavan avoimuus Osittain avoin julkaisukanava

Verkko-osoitehttps://doi.org/10.1093/eurjpc/zwaf271

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/505618726



Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
The Young Finns Study has been financially supported by the Academy of Finland: grants 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 255381, 256474, 283115, 319060, 320297, 314389, 338395, 330809, 104821, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for to Aition); European Research Council (grant 742927 for MULTIEPIGEN project); and Tampere University Hospital Supporting Foundation, Finnish Society of Clinical Chemistry, and the Cancer Foundation Finland. J.N. was funded by Finnish Cultural Foundation, Varsinais-Suomi Regional Fund, and the EVO fund of Turku University Hospital. K.P. was funded by the Academy of Finland Research Fellowship (no. 322112). T.T.L. was funded by The Sakari Alhopuro Foundation.


Last updated on